EGFR and non-small cell lung carcinoma: Hundreds of synthetic long peptides, RNA-, DNA-, and dendritic cell-based vaccines have reached clinical validation trials, and one successful example is a neoantigen peptide vaccine for EGFR-mutated non-small cell lung cancer [88].